

## Overview of CML related sessions at EHA Congress 2021

Virtual Meeting: June 9-17, 2021

All sessions will be held at CET (Central European Time)

Time slots	Sessions
June 16 (Wednesday) 9.00-9.45 Virtual Room 3	<p><b>Thematic Debates:</b> Interactive debates, where 2 or more speakers will present opposing positions followed by a discussion afterwards. <i>These sessions are held live.</i></p> <p><b>Pediatric Hematology:</b> Should children be treated differently than adults?</p> <p>Chair: C Putti (Italy)</p> <ul style="list-style-type: none"> <li>• Chronic Myeloid Leukemia: F Millot (France)</li> <li>• Myeloproliferative neoplasms: C Harrison (United Kingdom)</li> </ul>
Live Q&A June 16 (Wednesday) 11.00-11.45 Virtual Room 1	<p><b>SWG Sessions:</b> Chronic Myeloid Leukemia ELN-EHA SWG for CML <i>Will be released as on-demand content on Friday, June 11 at 9:00 CET</i></p> <p>Chair: R Hehlmann (Germany)</p> <ul style="list-style-type: none"> <li>• CML and COVID-19 - What do we know in 2021? D Rea (France)</li> <li>• The new ELN recommendations for treating CML: A Hochhaus (Germany)</li> <li>• CML and BCR-ABL monitoring: The foster child for molecular monitoring of hematologic neoplasms: N Cross (United Kingdom)</li> <li>• The CML genomics/HARMONY PLUS project: S Branford (Australia)</li> </ul>
Live Q&A June 16 (Wed.) 14.00-14.45	<p><b>Oral Session:</b> Response, resistance and treatment-free remission in CML</p>

Time slots	Sessions
Virtual Room 2	Chair/program: to be announced
<p><i>Live Q&amp;A</i> June 16 (Wednesday) 16.00-16.45 Virtual Room 1</p>	<p><b>Education Session:</b> Stem cells targeting in CML <i>Will be released as on-demand content on Friday, June 11 at 9:00 CET</i></p> <p>Chair: O Hantschel (Germany)</p> <p>Program:</p> <ul style="list-style-type: none"> <li>• CML Biology: M Deininger (United States)</li> <li>• Immune cell contexture and response: S Mustjoki (Finland)</li> <li>• Treatment-free remission in CML: FX Mahon (France)</li> </ul>
Advocacy & Patient Sessions	
<p>June 9 (Wednesday) 10.00-12.00 Virtual Room 1</p>	<p><b>Advocacy &amp; Patient sessions</b> <i>The presentations will be pre-recorded, but the sessions will be made available on their respective days, and are then available on-demand.</i></p> <p><b>EU Projects in Hematology</b></p> <p>Chairs: Speaker to be announced</p> <ul style="list-style-type: none"> <li>• HARMONY: speaker to be announced</li> <li>• T2EVOLVE - Accelerating development and improving access to CAR and TCR-engineered T cell therapy in Europe: M Hudecek (Germany)</li> <li>• GoCART from slow motion to fast forward: J Kuball (The Netherlands)</li> <li>• EuNet-INNOCHRON: H Pakadaki (Greece)</li> </ul>

Time slots	Sessions
June 9 (Wednesday) 13.00-16.00 Virtual Room 1	<b>EHA-Patient Joint Symposia</b> <ul style="list-style-type: none"> <li>EHA-Patient Joint Symposium 1: Affordable access (Chair: to be announced)</li> </ul>
June 11 (Friday) 13.00-14.00 Virtual Room 2	<b>EHA-Patient Joint Symposia</b> <ul style="list-style-type: none"> <li>EHA-Patient Joint Symposium 2: Lessons from COVID-19 (Chair: to be announced)</li> </ul>
June 12 (Saturday) 10.00-12.45 Virtual Room 2	<b>EHA-Patient Joint Symposia</b> <ul style="list-style-type: none"> <li>EHA-Patient Joint Symposium 3: Clinical trials (Chair: to be announced)</li> </ul>
<b>Oral Presentations</b>	
CML - Biology and Translational Research	<ul style="list-style-type: none"> <li>S150: LOSS OF G0/G1 SWITCH TO GENE2 (G0S2) IN CML PROMOTES TKI RESISTANCE BY Deregulation the Mitochondrial Electron Transport Chain (Gonzalez M et al.)</li> <li>S151: MITOCHONDRIAL DNA MUTATIONS ARE ASSOCIATED WITH RESPONSE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS (Pagani I et al.)</li> </ul>
CML - Clinical	<ul style="list-style-type: none"> <li>S152: FINAL ANALYSIS OF A PAN-EUROPEAN STOP TYROSINE KINASE INHIBITOR TRIAL IN CHRONIC MYELOID LEUKEMIA: THE EURO-SKI STUDY (Saussele S et al.)</li> <li>S153: OPTIC PRIMARY ANALYSIS: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB (PON) (Cortes J et al.)</li> <li>S154: COVID-19 INFECTION IN CHRONIC MYELOID LEUKEMIA AFTER 1 YEAR OF THE PANDEMIC IN ITALY: A CAMPUS CML ANALYSIS (Breccia M et al.)</li> <li>S155: THE LOSS OF LIFE EXPECTANCY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A</li> </ul>

Time slots	Sessions
	POPULATION-BASED STUDY IN THE NETHERLANDS, 1989-2918 (Maas C et al.)
<b>e-Posters</b>	
CML – Biology and Translational Research	<ul style="list-style-type: none"> <li>• EP655: NEUTROPHIL EXTRACELLULAR TRAPS ARE INCREASED IN CHRONIC MYELOID LEUKEMIA AND ARE DIFFERENTLY AFFECTED BY TYROSINE KINASE INHIBITORS (Telerman A et al.)</li> <li>• EP656: PROFILES OF NK CELL SUBSETS ARE ASSOCIATED WITH SUCCESSFUL TYROSINE KINASE INHIBITOR DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA AND CHANGE FOLLOWING INTERFERON TREATMENT (Kong J et al.)</li> <li>• EP657: TNF-MEDIATED CML CELL SURVIVAL RESISTS TKI TREATMENT AND THIS CAN BE TARGETED BY IKK2-INHIBITION (Bütow M et al.)</li> <li>• EP658: AGE-RELATED DNA DAMAGE RESPONSE (DDR) IN HEMATOPOIETIC STEM CELLS FROM CHRONIC MYELOID LEUKEMIA PATIENTS WHO ATTEMPTED TKI DISCONTINUATION (Manfroni C et al.)</li> <li>• EP659: ASSESSMENT OF LEUKEMIC STEM CELL CD26+ IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE (Bengio R et al.)</li> <li>• EP660: EUTOS EXPERIENCE OF STANDARDIZATION OF MOLECULAR MONITORING FOR CML (2016-2020). USE OF SECONDARY BCR-ABL1 REFERENCE MATERIALS FOR CONVERSION FACTOR VALIDATION AND ASSESSMENT OF MR4.5 DETECTION (White H et al.)</li> <li>• EP661: ANALYSIS OF MRNA AND DNA LEVEL OF ATYPICAL BCR-ABL1 TRANSCRIPTS IN CML PATIENTS OUTLINED AN ELIGIBILITY FOR TKI STOPPING (Zizkova H et al.)</li> <li>• EP662: ANALYSIS OF MYELOID MUTATIONS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND THEIR ASSOCIATION WITH ADVERSE EVENTS AND RELAPSE AFTER DISCONTINUATION (Segura Diaz A et al)</li> <li>• EP663: COMPREHENSIVE IMMUNOPROFILE OF NK CELLS FROM CML PATIENTS IN TFR REVEALS A POSSIBLE ROLE OF MEMORY-LIKE NK CELLS (Belen Sanchez M et al.)</li> <li>• EP664: TARGETING THE LEUKEMIC STEM CELL NICHE BY PI3K INHIBITORS IN CHRONIC</li> </ul>

Time slots	Sessions
	<p>MYELOID LEUKEMIA TO OVERCOME LEUKEMIC STEM CELL (Filik Y et al.)</p> <ul style="list-style-type: none"> <li>• EP665: RARE MUTATIONS IN BCR-ABL THE KINASE DOMAIN IN CHRONIC MYELOID LEUKEMIA PATIENTS (Delamer R et al.)</li> </ul>
CML - Clinical	<ul style="list-style-type: none"> <li>• EP666: NEGATIVE PROGNOSTIC IMPACT OF HIGH-RISK ADDITIONAL CYTOGENETIC ABNORMALITIES IN ADDITION TO THE ELTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (Kockerols CB et al)</li> <li>• EP667: TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE FOLLOWING FRONTLINE NILOTINIB: RESULTS FROM JALSG N-STOP216 (Takahashi N et al.)</li> <li>• EP668: TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE FOLLOWING FRONTLINE DASATINIB: RESULTS FROM JALSG D-STOP216 (Minami Y et al.)</li> <li>• EP669: COMPARISON OF THE SOKAL AND EUTOS LONG-TERM SURVIVAL SCORES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA RECEIVING TYROSINE KINASE INHIBITORS (Zhang X et al.)</li> <li>• EP670: ASCIMINIB RESPONSES IN PONATINIB-PRETREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA (Luna A et al.)</li> <li>• EP671: OUTCOMES BEFORE AND AFTER DOSE REDUCTION IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA RECEIVING BOSUTINIB OR IMATINIB (Deininger M et al.)</li> <li>• EP672: SECOND-LINE BOSUTINIB FOR PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: FINAL 10-YEAR RESULTS OF A PHASE 1/2 STUDY (Gambarcorti-Passerini C et al.)</li> <li>• EP673: TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH LOW-DOSE TKIS. A FEASIBLE OPTION ALSO IN THE REAL-LIFE SETTING? (Iurlo A et al.)</li> <li>• EP674: COVID-19 IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: DISEASE OUTCOMES AND FIRST VACCINATION DATA IN RUSSIAN FEDERATION (Chelycheva E et al.)</li> </ul>

Time slots	Sessions
	<ul style="list-style-type: none"> <li>• EP675: ASSOCIATION OF CREATINE KINASE ELEVATION WITH CLINICAL OUTCOMES IN CHRONIC MYELOID LEUKEMIA (Bankar A et al.)</li> <li>• EP676: FRONTLINE TREATMENT APPROACHES FOR CML IN MYELOID BLAST PHASE: A SINGLE-CENTER EXPERIENCE OVER 2 DECADES (Saxena K et al.)</li> <li>• EP677: EFFECT OF COMORBIDITIES ON PATIENT RESPONSES WITH FIRST-LINE DASATINIB VERSUS IMATINIB IN CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: EXPLORATORY POST HOC ANALYSIS OF DASISION (Breccia M et al.)</li> <li>• EP678: HYDROXYUREA PRE-TREATMENT IN CHRONIC MYELOID LEUKEMIA PATIENTS: MORE HARM THAN GOOD? (Kockerols CB et al.)</li> <li>• EP679: FRENCH REAL-LIFE OBSERVATIONAL STUDY 'TOPASE' EVALUATING SAFETY AND EFFICACY OF PONATINIB CONFIRMS INDUCTION OF DEEP MOLECULAR RESPONSES IN 110 RESISTANT OR INTOLERANT CML PATIENTS (Turhan A et al.)</li> <li>• EP680: WITHDRAWAL SYNDROME AFTER TYROSINE KINASE INHIBITORS DISCONTINUATION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (Petrova A et al.)</li> <li>• EP681: FIRST INTERIM RESULTS OF THE RUSSIAN PROSPECTIVE STUDY OF REDUCTION AND DISCONTINUATION TREATMENT OF TKI (READIT) IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE (Gurianova M et al.)</li> <li>• EP682: A SURVEY OF HEALTHCARE PROFESSIONALS IN THE UNITED KINGDOM TO DESCRIBE CURRENT PATHWAYS AND MANAGEMENT PRACTICES IN CHRONIC MYELOID LEUKAEMIA: THE ADAPT CML SURVEY (Mead A et al.)</li> <li>• EP683: TREATMENT ADHERENCE IN CHRONIC MYELOID LEUKEMIA PATIENTS RECEIVING TYROSINE KINASE INHIBITORS (Benlazar S et al.)</li> <li>• EP684: THE EFFECT OF BODY MASS INDEX ON EFFICACY AND SAFETY OF BOSUTINIB OR IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (Brümmendorf T et al)</li> </ul>

Time slots	Sessions
<b>Publication only</b>	
CML – Biology and Translational Research	<ul style="list-style-type: none"> <li>• PB1509: TYROSINE KINASE INHIBITORS DOWNREGULATE MIRNA EXPRESSION IN K562 CELL LINE (Freue JM et al.)</li> <li>• PB1510: PATTERN OF MINIMAL RESIDUAL DISEASE IN TUNISIAN CHRONIC MYELOID LEUKEMIA PATIENTS (Frikha R et al.)</li> <li>• PB1511: MI-30-B AS A HOUSEKEEPING GENE POR MIRNA QPCR QUANTIFICATION IN CHRONIC MYELOID LEUKEMIA (Freue JM et al.)</li> <li>• PB1512: STUDY OF TELOMERE LENGTH IN PATIENTS WITH CHRONIC MYELOLEUKOSIS (Lyamkina A et al.)</li> </ul>
CML - Clinical	<ul style="list-style-type: none"> <li>• PB1513: PULMONARY HYPERTENSION IN NEWLY DIAGNOSED AND TYROSINE KINASE INHIBITOR-TREATED PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA: A SINGLE-CENTER RETROSPECTIVE ANALYSIS (Song I et al.)</li> <li>• PB1514: KARYOTYPING CML PATIENTS IN TANZANIA USING DRY SPOT CARDS: A FEASIBLE AND NECESSARY DIAGNOSTIC PERFORMANCE FOR BETTER TREATMENT OUTCOME (Henke O et al.)</li> <li>• PB1515: E13A2, E14A2 TRANSCRIPTS: DO THEY HAVE A DIFFERENT IMPACT ON OUTCOME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA? (Garofalaki M et al.)</li> <li>• PB1516: CHRONIC MYELOID LEUKEMIA – THE CHALLENGE OF FRONTLINE TKI SELECTION 20 YEARS AFTER IMATINIB (Tsonis I et al.)</li> <li>• PB1517: A MULTICENTER REAL-WORD EVIDENCE STUDY IN THE SWISS TREATMENT LANDSCAPE OF CHRONIC MYELOID LEUKEMIA (Balabanov S et al.)</li> <li>• PB1518: IMPACT OF LOW-DOSES TKIS IN THE RESPONSE OF CHRONIC PHASE CML PATIENTS: A 20-YEAR RETROSPECTIVE ANALYSIS. (Martínez Tobar L et al.)</li> <li>• PB1520: RETROSPECTIVE REAL-WORLD COMPARISON OF CLINICAL AND ECONOMIC BURDEN BETWEEN FIRST-GENERATION AND SECOND-GENERATION TYROSINE KINASE INHIBITORS (TKIS) IN CHRONIC MYELOID LEUKEMIA (CML) (Russel-Smith T et al.)</li> </ul>

Time slots	Sessions
	<ul style="list-style-type: none"> <li>• PB1521: TREATMENT SELECTION IN CML: EFFECT OF ONLINE EDUCATION ON CLINICIAN KNOWLEDGE AND CONFIDENCE (Taylor A et al.)</li> <li>• PB1522: CLINICAL CHARACTERISTICS, DISEASE EVOLUTION AND SURVIVAL IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA, BCR-ABL-1+ AND MUTATION T315I (Goranova V et al.)</li> <li>• PB1523: TREATMENT OF CHRONIC MYELOID LEUKEMIA IN CHILDREN WITH TYROSIN KINASE INHIBITORS (Karadaş N et al.)</li> <li>• PB1524: QTC PROLONGATION AND SUDDEN CARDIAC DEATH AS A MANIFESTATION OF CARDIOTOXICITY (Makeeva L et al.)</li> <li>• PB1525: THE DIAGNOSIS, TREATMENT AND MONITORING OF PATIENTS WITH CHRONIC MYELOID LEUKAEMIA: THE IMPACT OF ELN GUIDELINES ON CLINICAL PRACTICE IN A DISTRICT GENERAL HOSPITAL (Sivakumaran S et al.)</li> <li>• PB1526: DOSE REDUCTION OF ITKS IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA. RETROSPECTIVE STUDY OF A SINGLE CENTER EXPERIENCE: SAFETY, EFFICIENCY AND ECONOMIC IMPACT. (Marco de Lucas F et al.)</li> <li>• PB1527: DISCONTINUATION OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH CML WITH DEEP MOLECULAR RESPONSE IN SOUTH OF TUNISIA (Mallek R et al.)</li> <li>• PB1528: PARAPROTEINEMIA PREVALENCE AND CHARACTERISTICS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (Berger T et al.)</li> <li>• PB1530: CHRONIC MYELOID LEUKEMIA WITH THREE-WAY TRANSLOCATION T(4;9;22) AND MULTIPLE MYELOMA – A RARE CASE OF COMORBIDITY (Petkova N et al.)</li> <li>• PB1531: CHRONIC MYELOID LEUKEMIA AS A SECONDARY MALIGNANCY IN A PATIENT WITH SPLENIC MARGINAL ZONE LYMPHOMA: A CASE REPORT (Huang H et al.)</li> <li>• PB1532: FISH VERSUS REAL-TIME QUANTITATIVE PCR FOR MONITORING OF MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKAEMIA PATIENTS ON TYROSINE KINASE INHIBITOR THERAPY (Maseh Haidary A et al.)</li> <li>• PB1533: COMPLETE REMISSION OF PSORIASIS IN CML LADY TREATED WITH DASATINIB: JOYFUL EXPERIENCE (Eisa N et al.)</li> </ul>



Time slots	Sessions
	<ul style="list-style-type: none"> <li data-bbox="566 274 1798 336">• PB1534: CHRONIC MYELOID LEUKEMIA: ATYPICAL PRESENTATION WITH ISOLATED EXTREME THROMBOCYTOSIS (Freue JM et al.)</li> <li data-bbox="566 357 1823 454">• PB1535: COMPLEX CYTOGENETIC ABNORMALITIES IN CHRONIC MYELOID LEUKEMIA RESULTING IN EARLY PROGRESSION TO BLAST CRISIS: A CASE REPORT (Maseh Haidary A et al.)</li> </ul>